---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-101410"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2025-10-22T23:59:59+00:00"
generated_at: "2026-05-17T02:51:44.561238+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics updates on GX-03 phase 2 eczema trial: 25% enrolled, topline 2026; $85M GEM facility

## Summary
- Phase 2 trial of GX-03 (topical IL-36/IL-31 inhibitor) for moderate-severe eczema: ~25% of targeted sample completed, no safety concerns; topline results expected in 2026.
- Company completed dilution-sparing direct listing with $85M GEM Global Yield on-demand financing vehicle to reduce reliance on future equity offerings.
- Intranasal vaccine initiative advancing; in-vivo studies scheduled to commence in Q4 2025.
- Shareholder webinar held today, October 22, 2025 at 2:00 PM ET to review milestones and capital strategy.

## SEC filing metadata
- accession: 0001104659-25-101410
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2025-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000110465925101410/0001104659-25-101410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000110465925101410/tm2529242d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-101410
- JSON: https://secwatch.observer/filing/0001104659-25-101410.json
- Plain text: https://secwatch.observer/filing/0001104659-25-101410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.